Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors

International Journal of Cardiology

Volumn 168, Issue 1, 2013, Pages 403-406

  Badr Eslam, Roza ^a   Lang, Irene M ^a   Koppensteiner, Renate ^a   Calatzis, Andreas ^b   Panzer, Simon ^a   Gremmel, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antiplatelet therapy; PAR 1; PAR 4; Thrombin

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 AGONIST; PROTEINASE ACTIVATED RECEPTOR 4; PROTEINASE ACTIVATED RECEPTOR 4 AGONIST; PROTON PUMP INHIBITOR; THROMBIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESPONSE; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIPLE ELECTRODE IMPEDANCE AGGREGOMETRY; PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

ANTIPLATELET THERAPY; PAR-1; PAR-4; THROMBIN;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PIPERAZINES; PLATELET ACTIVATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTOR, PAR-1; RECEPTORS, PURINERGIC P2Y12; RECEPTORS, THROMBIN; THIOPHENES; TICLOPIDINE;

EID: 84883777579     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.09.103     Document Type: Article

References (33)

1. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
2. M. Cattaneo Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance Arterioscler Thromb Vasc Biol 24 2004 1980 1987
3. D. Sibbing, S. Braun, and T. Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
4. T. Geisler, H. Langer, and M. Wydymus Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur Heart J 27 2006 2420 2425
5. M.J. Price, S. Endemann, and R.R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
6. P.A. Gurbel, K.P. Bliden, and K. Guyer Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J Am Coll Cardiol 46 2005 1820 1826
7. R. Marcucci, A.M. Gori, and R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
8. D. Aradi, A. Komócsi, and A. Vorobcsuk Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis Am Heart J 160 2010 543 551
9. J.W. Eikelboom, J.I. Weitz, and A. Budaj Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes Eur Heart J 23 2002 1771 1779
10. M.L. Kahn, M. Nakanishi-Matsui, M.J. Shapiro, H. Ishihara, and S.R. Coughlin Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin J Clin Invest 103 1999 879 887
11. A.J. Leger, L. Covic, and A. Kuliopulos Protease-activated receptors in cardiovascular diseases Circulation 114 2006 1070 1077
12. D. Dormann, K.J. Clemetson, and B.E. Kehrel The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity Blood 96 2000 2469 2478
13. G. Soslau, R. Class, and D.A. Morgan Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib J Biol Chem 276 2001 21173 21183
14. F. Adam, M.C. Guillin, and M. Jandrot-Perrus Glycoprotein Ib-mediated platelet activation. A signalling pathway triggered by thrombin Eur J Biochem 270 2003 2959 2970
15. S. Kim, C. Foster, and A. Lecchi Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling Blood 99 2002 3629 3636
16. S.S. Smyth, D.S. Woulfe, and J.I. Weitz G-protein-coupled receptors as signaling targets for antiplatelet therapy Arterioscler Thromb Vasc Biol 29 2009 449 457
17. F.A. Ofosu, L. Dewar, and S.J. Craven Coordinate activation of human platelet protease-activated receptor-1 and -4 in response to subnanomolar alpha-thrombin J Biol Chem 283 2008 26886 26893
18. K. Jurk, U.R. Jahn, and H. Van Aken Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1) Thromb Haemost 91 2004 334 344
19. P. Tricoci, Z. Huang, and C. Held Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N Engl J Med 366 2012 20 33
20. P. Tricoci, Z. Huang, and C. Held Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N Engl J Med 366 2012 20 33
21. D.J. Angiolillo, D. Capodanno, and S. Goto Platelet thrombin receptor antagonism and atherothrombosis Eur Heart J 31 2010 17 28
22. V.L. Serebruany, M. Kogushi, D. Dastros-Pitei, M. Flather, and D.L. Bhatt The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease Thromb Haemost 102 2009 111 119
23. S. Chackalamannil, Y. Wang, and W.J. Greenlee Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity J Med Cem 51 2008 3061 3064
24. M. Chintala, J. Strony, B. Yang, S. Kurowski, and Q. Li SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys Arterioscler Thromb Vasc Biol 30 2010 2143 2149
25. T. Gremmel, A. Calatzis, and S. Steiner Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel? Platelets 21 2010 515 521
26. J.A. Jakubowski, C.D. Payne, and G.J. Weerakkody Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects J Cardiovasc Pharmacol 49 2007 167 173
27. M. Holinstat, B. Voss, M.L. Bilodeau, J.N. McLaughlin, J. Cleator, and H.E. Hamm PAR4, but not PAR1, signals human platelet aggregation via Ca2 + mobilization and synergistic P2Y12 receptor activation J Biol Chem 281 2006 26665 26674
28. H. Shankar, A. Garcia, J. Prabhakar, S. Kim, and S.P. Kunapuli P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation J Thromb Haemost 4 2006 638 647
29. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation Thromb Haemost 101 2009 333 339
30. L. Bonello, U.S. Tantry, and R. Marcucci Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
31. D.A. Morrow, E. Braunwald, and M.P. Bonaca TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherthrombotic events N Engl J Med 366 2012 1404 1413
32. D. Sibbing, S. Schulz, and S. Braun Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement J Thromb Haemost 8 2010 250 256
33. D. Sibbing, T. Morath, and S. Braun Clopidogrel response status assessed with multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting Thromb Haemost 103 2010 151 159